spravato - Search News

FDA Approves ‘Spravato’ Nasal Spray

Can a Nasal Spray Really Help Treat Depression? Here's What to Know About Spravato

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

Monthly Prescribing Reference · 1d

Spravato Approved as Monotherapy for Treatment-Resistant Depression

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, placebo-controlled, phase 4 TRD4005 trial.

Popular Science · 3d

FDA approves first-of-its-kind nasal spray for severe depression

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.

1d

Does Medicare cover ketamine infusions for mental health conditions?

Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...

J&J’s Spravato Makes Headway in Tough Depression Space With Monotherapy Approval

Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...

Johnson & Johnson's Spravato gains FDA nod to be used as a monotherapy

Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...

Hosted on MSN1d

FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with it

On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...

1d

Weekly Roundup: 14 Health Press Releases You Need to See

With thousands of press releases published each week, it can be difficult to keep up with everything on. To help healthcare ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results